Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g Vct5 Regulatory News (MIG5)

Share Price Information for Maven I&g Vct5 (MIG5)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 30.40
Bid: 29.40
Ask: 31.40
Change: 0.00 (0.00%)
Spread: 2.00 (6.803%)
Open: 30.40
High: 30.40
Low: 30.40
Prev. Close: 30.40
MIG5 Live PriceLast checked at -
Maven Income and Growth VCT 5 is an Investment Trust

To invest in a diversified portfolio of later-stage UK private companies to provide long-term capital appreciation and generate maintainable levels of income for shareholders.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Related Party Transaction

10 Mar 2022 07:00

RNS Number : 2721E
Maven Income and Growth VCT 5 PLC
10 March 2022
 

MAVEN INCOME AND GROWTH VCT 5 PLC

LEI: 213800DMF84841RMWX35

9 March 2022

Related Party Transaction

 

Maven Income and Growth VCT 5 PLC (the "Company") announces that, following a review and taking into account peer group analysis, the Company's administrative and secretarial fee and performance fee arrangements with the Company's investment manager, Maven Capital Partners UK LLP ("Maven"), have changed.

 

With effect from 1 December 2021, the annual administrative and secretarial fee payable to Maven will be increased from £86,000, to £100,000, payable quarterly in arrears and subject to an annual adjustment, calculated on 1 December each year.

 

Maven will continue to be entitled to a performance fee on a revised basis with effect from 1 December 2021 should certain criteria be met. The updated key terms of the calculation of the performance fee are summarised below:

§ the performance fee in respect of private equity investments has been increased to 15 per cent.; and

§ the performance fee in respect of the Company's quoted portfolio is now payable on all quoted investments (excluding any investment trusts).

Maven has agreed to decrease the cap on the total expenses payable by the Company from 3.25 per cent. to 3.0 per cent. of the Company's net assets per annum, adjusted annually and excluding performance fees and exceptional costs.

 

Under the Listing Rules of the FCA, a related party includes the investment manager of a closed-ended investment fund. Maven is therefore a related party of the Company under the Listing Rules and the increase in the fees payable by the Company to Maven is a transaction to which Listing Rule 11.1.10R applies.

 

The Board's agreement to change the administrative and secretarial fee and the performance fee payable to Maven is a smaller related party transaction as defined in LR11.1.10R.

 

Issued on behalf of the Board

Maven Capital Partners UK LLP

Company Secretary

 

9 March 2022

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBKCBPDBKBFNK
Date   Source Headline
23rd Apr 20242:27 pmRNSResult of AGM
19th Apr 202412:17 pmRNSIssue of Supplementary Prospectus
5th Apr 20243:49 pmRNSIssue of Equity
27th Mar 202410:31 amRNSIssue of Equity
22nd Mar 20244:25 pmRNSStatement re Offer for Subscription
22nd Mar 202410:14 amRNSIssue of Supplementary Prospectus
20th Mar 20243:48 pmRNSUnaudited Net Asset Value
8th Mar 20242:57 pmRNSAnnual Financial Report
15th Feb 20244:45 pmRNSTransaction in Own Shares
8th Feb 202410:33 amRNSDirector/PDMR Shareholding
8th Feb 202410:12 amRNSIssue of Equity
7th Feb 20243:09 pmRNSDividend Declaration
19th Dec 20233:28 pmRNSIssue of Equity
18th Dec 20235:24 pmRNSUnaudited Net Asset Value
9th Nov 20233:51 pmRNSResult of General Meeting
20th Oct 20234:13 pmRNSTransaction in Own Shares
13th Oct 20234:56 pmRNSPublication of a Prospectus
4th Oct 20234:03 pmRNSNet Asset Value(s)
29th Aug 20239:15 amRNSDirectorate Change
24th Jul 202311:16 amRNSHalf-year Report
21st Jul 20234:43 pmRNSTransaction in Own Shares
21st Jul 20239:48 amRNSIssue of Equity
17th Jul 202310:57 amRNSNet Asset Value - Dividend Investment Scheme
11th Jul 20234:47 pmRNSNet Asset Value
6th Jul 20234:01 pmRNSStatement re Intended Offers for Subscription
14th Jun 202310:33 amRNSDividend Declaration
2nd Jun 20239:48 amRNSIssue of Equity
5th May 202310:23 amRNSIssue of Equity - Dividend Investment Scheme
27th Apr 20233:57 pmRNSTransaction in Own Shares
27th Apr 20231:04 pmRNSIssue of Supplementary Prospectus
26th Apr 202311:39 amRNSNet Asset Value - Dividend Investment Scheme
25th Apr 20233:14 pmRNSNet Asset Value(s)
25th Apr 202312:50 pmRNSResult of AGM
5th Apr 202312:32 pmRNSIssue of Equity
29th Mar 20232:19 pmRNSIssue of Supplementary Prospectus
23rd Mar 20235:18 pmRNSAnnual Financial Report
3rd Mar 20239:56 amRNSIssue of Equity
21st Feb 20234:44 pmRNSTransaction in Own Shares
8th Feb 202310:24 amRNSDirector/PDMR Shareholding
8th Feb 20239:48 amRNSIssue of Equity
1st Feb 20233:25 pmRNSUnaudited NAV and Proposed Final Dividend
9th Nov 20223:02 pmRNSResult of General Meeting
4th Nov 20223:25 pmRNSTransaction in Own Shares
26th Oct 20223:53 pmRNSTransaction in Own Shares
7th Oct 20224:28 pmRNSPublication of a Prospectus
4th Oct 20223:30 pmRNSChange of Auditor
4th Oct 20221:35 pmRNSNet Asset Value(s)
26th Aug 202210:14 amRNSIssue of Equity
22nd Aug 20229:36 amRNSStatement re Dividend Investment Scheme
11th Aug 20224:47 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.